MedTrace Logo

Performance of CHLOE Algorithm on the Prediction of Blastocyst Formation

NCT05455281 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2025-03-05

No results posted yet for this study

Summary

This is an observational, prospective, single-arm, multi-center, clinical study to evaluate the performance of CHLOE, an Artificial Intelligence (AI)-based software application, as adjunct information to support identifying embryos on Day 3 that are most likely to form blastocysts.

Conditions

  • Fertility Disorders

Interventions

DEVICE

CHLOE

CHLOE is designed to automatically analyze events related to embryo development from Time Lapse Incubator (TLI) images and provide prediction on the likelihood of embryos developing to the blastocyst. This information can assist embryologists and IVF professionals in the selection of the most viable embryo for transfer or freezing, when there are multiple embryos deemed suitable.

Sponsors & Collaborators

  • Fairtility

    lead INDUSTRY

Principal Investigators

  • Yossi Gilgun-Sherki, PhD, MBA · Head of Clinical and Regulatory Affairs

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-27
Primary Completion
2023-06-27
Completion
2023-07-27
FDA Device
Yes

Countries

  • United States
  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05455281 on ClinicalTrials.gov